Additionally, combining JAK2 inhibitors with epigenetic modifiers (e.g., histone deacetylase inhibitors (HDAC inhibitors) or DNA methyltransferase inhibitors) can reprogram the leukemia cell epigenome, making them more susceptible to both JAK2 inhibition and chemotherapeutic agents. Here, JAK2 is linked to leukemia.